Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05251363 · ClinicalTrials.gov registry record · NA
BIOTRONIK Conduction System Pacing With the Solia Lead
A NA study, sponsored by Biotronik.
- Completed
- Registry status
- NA
- Development phase
- 194
- Enrollment target
NCT05251363 is a NA study that has completed, run by Biotronik. The registered enrollment target is 194 participants.
The verdict
NCT05251363, a NA study, has completed, sponsored by Biotronik.
- COMPLETED
- Registry status
- NA
- Development phase
- 194 participants
- Enrollment target
Study Summary
The purpose of the BIO-CONDUCT study is to demonstrate the safety and effectiveness of the BIOTRONIK Solia S pacing lead when implanted in the left bundle branch (LBB) area. Safety will be assessed by evaluating serious adverse device effects that occur through 3 months post-implant. Efficacy will be assessed by evaluating implant success rate.
Interventions
- DEVICE Solia S lead
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 194 participants |
| Start Date | 2022-12-12 |
| Est. Completion | 2024-10-08 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05251363
The ClinicalTrials.gov registry entry for NCT05251363 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 194 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biotronik, which has 30 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Solia S lead is the first listed.
NCT05251363 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05251363 about?
NCT05251363 is a clinical study titled "BIOTRONIK Conduction System Pacing With the Solia Lead". The purpose of the BIO-CONDUCT study is to demonstrate the safety and effectiveness of the BIOTRONIK Solia S pacing lead when implanted in the left bundle branch (LBB) area. Safety will be assessed by evaluating serious adverse device effects that occur through 3 months post-implant. Efficacy will b...
What is the current status of trial NCT05251363?
This trial is currently completed. It is a NA study. The enrollment target is 194 participants. The study started on 2022-12-12. Estimated completion is 2024-10-08.
What interventions are being tested in trial NCT05251363?
The interventions under investigation include: Solia S lead (DEVICE).
Who is sponsoring clinical trial NCT05251363?
This trial is sponsored by Biotronik, which has 30 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.